This trial will explore the relationship between a patient's genetic makeup and how well they respond to the drug etoposide, as well as any side-effects they may experience.
- Small Cell Lung Cancer
2 Primary · 0 Secondary · Reporting Duration: Duration at least 180 days
Awards & Highlights
2 Treatment Groups
ETOPOSIDE - Study
1 of 2
ETOPOSIDE - Usual
1 of 2
600 Total Participants · 2 Treatment Groups
Primary Treatment: ETOPOSIDE - Study · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 22 - 75 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Would it be possible for me to participate in this clinical trial?
"This clinical trial is looking for 600 participants with small cell lung carcinoma, aged 22 to 75. In order to be eligible, patients must have had the condition for at least 180 days and must be able to have a lung tissue biopsy. Additionally, the following criteria must be met: 1. Clinical diagnosis of Small Cell Lung Cancer (SCLC), 2. Clinical lung tissue biopsy diagnosis of SCLC, 3. Suitable for enough lung tissue biopsy of SCLC, 4. Random and double blind, 5. Measurable disease, 6. Adequate organ functions." - Anonymous Online Contributor
What conditions does ETOPOSIDE - Study help treat?
"ETOPOSIDE - This medication is most frequently utilized to manage [small cell lung cancer](https://www.withpower.com/clinical-trials/small-cell-lung-cancer) (sclc). Additionally, it can be useful in treating metastatic thymic cancer, leukemia, myelocytic, acute, and advance directives." - Anonymous Online Contributor
Can people below the age of 20 participate in this clinical research?
"The age limit for this study are individuals who are at least 22 but no older than 75." - Anonymous Online Contributor
What does the research say about using etoposide to treat patients?
"There are presently 322 clinical trials underway researching the efficacy of ETOPOSIDE - Study. 95 of those are in the final Phase 3. Many of these studies are based in Houston, Texas, but there are a total of 15464 locations running these trials." - Anonymous Online Contributor
Do we have the regulatory go-ahead to use ETOPOSIDE in this research?
"ETOPOSIDE - Study has been scored a 3 for safety by our team at Power. This is due to this being a Phase 3 trial, which signifies that there is data affirming its efficacy as well as multiple rounds of data affirming its safety." - Anonymous Online Contributor